Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
Pharmacol Ther. 2020 Oct;214:107603. doi: 10.1016/j.pharmthera.2020.107603. Epub 2020 Jun 15.
Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such 'living' therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy.
免疫疗法包括基因修饰的免疫细胞，已成为癌症治疗的一个有前途的平台。这种针对肿瘤抗原的“活”疗法在越来越多的临床研究中以持久反应的形式在许多癌症患者中取得了成功。此外，大量正在进行的研究旨在引入可靠的方法来识别肿瘤抗原。此外，正在将技术和生物技术的发展应用于基因修饰免疫细胞的生成和扩增。在这篇综述中，我们总结和讨论了肿瘤抗原图谱以及基因修饰免疫细胞生成方面的最新进展和当前挑战，着眼于它们作为单一疗法或联合疗法的临床疗效。
